BDTX (Black Diamond Therapeutics, Inc.) רווח למניה בארבעת הרבעונים האחרונים

Black Diamond (BDTX) relies on an advanced MAP system that enables the identification of hidden tumor targets inaccessible to standard therapy methods. The primary growth driver will be the upcoming results from Phase I and II trials of its lung cancer drug, while the lack of revenue has already been priced in by investors. This daily price chart, featuring an EPS of -303.80, complements the data regarding the MasterKey platform for combating rare mutations.
Black Diamond Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (BDTX)

Effective delegation of oncology trials to external contractors while retaining IP rights provides Black Diamond (BDTX) with operational flexibility. This model directly impacts net income dynamics, which this indicator mathematically captures. The metric measures the rolling annual rate of change in earnings per share over twelve months, revealing the actual fundamental trend. By analyzing the current EPS TTM YoY growth rate, an investor can assess the impact of currency fluctuations on the business's final margins.